NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis $1.18 +0.10 (+9.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.09▼$1.1850-Day Range$1.01▼$1.6752-Week Range$0.99▼$7.14Volume182,963 shsAverage Volume440,208 shsMarket Capitalization$49.02 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Carisma Therapeutics alerts: Email Address Carisma Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside578.0% Upside$8.00 Price TargetShort InterestHealthy5.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.56) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.29 out of 5 starsMedical Sector350th out of 936 stocksPharmaceutical Preparations Industry163rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.11% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 47.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 4.1 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for CARM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Carisma Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Carisma Therapeutics Stock (NASDAQ:CARM)Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Read More CARM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARM Stock News HeadlinesJuly 1, 2024 | prnewswire.comCarisma Therapeutics Announces Changes to its Board of DirectorsJune 27, 2024 | prnewswire.comCarisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaJuly 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.June 25, 2024 | prnewswire.comCarisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid TumorsJune 25, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Stifel 2024 Cell Therapy ForumJune 13, 2024 | prnewswire.comCarisma Therapeutics Announces Adjournment of Annual Meeting of StockholdersMay 30, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 20, 2024 | msn.comCarisma Therapeutics Launches First Human Trial for CAR-Monocyte TherapyJuly 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer TherapyMay 17, 2024 | markets.businessinsider.comThe Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 ExpertsMay 16, 2024 | prnewswire.comCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteMay 14, 2024 | finance.yahoo.comIs There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?May 13, 2024 | msn.comCarisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis TreatmentMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment DevelopmentsMay 10, 2024 | markets.businessinsider.comBuy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market GrowthMay 9, 2024 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | prnewswire.comCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsSee More Headlines Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+578.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,880,000.00 Net Margins-538.81% Pretax Margin-539.53% Return on Equity-215.95% Return on Assets-80.58% Debt Debt-to-Equity Ratio0.08 Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$15.07 million Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.79Miscellaneous Outstanding Shares41,543,000Free Float34,481,000Market Cap$49.02 million OptionableNo Data Beta1.51 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Steven Kelly (Age 59)President, CEO & Director Comp: $786.91kMr. Michael Klichinsky Ph.D. (Age 34)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Comp: $525.43kMr. Richard S. Morris CPA (Age 50)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Comp: $584.85kDr. Saar Gill M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardMr. Eric H. Siegel J.D. (Age 59)MBA, General Counsel & Corporate Secretary Ms. Terry ShieldsSenior Vice President of Human ResourcesMr. Tom Wilton (Age 50)Chief Business Officer Dr. Eugene P. Kennedy F.A.C.S. (Age 55)M.D., Chief Medical Officer Mr. Kenneth LockeSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsCytosorbentsNASDAQ:CTSOExagenNASDAQ:XGNAspira Women's HealthNASDAQ:AWHLifeVantageNASDAQ:LFVNAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 11,200 shares on 5/10/2024Ownership: 3.803%Empowered Funds LLCSold 21,150 shares on 5/7/2024Ownership: 0.065%View All Institutional Transactions CARM Stock Analysis - Frequently Asked Questions How have CARM shares performed this year? Carisma Therapeutics' stock was trading at $2.93 at the beginning of the year. Since then, CARM stock has decreased by 59.7% and is now trading at $1.18. View the best growth stocks for 2024 here. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. The firm earned $3.40 million during the quarter, compared to analyst estimates of $3.90 million. Carisma Therapeutics had a negative net margin of 538.81% and a negative trailing twelve-month return on equity of 215.95%. How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.